Olanzapine Versus Haloperidol: Which Can Control Stuttering Better?

Overview

Journal Int J Prev Med

Date 2013 Jun 19

PMID 23776736

Citations 5

Authors

Vahid Shaygannejad

Seyed Ahmadreza Khatoonabadi

Bijan Shafiei

Majid Ghasemi

Farzad Fatehi

Rokhsareh Meamar

Leila Dehghani

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to compare the effects of olanzapine versus haloperidol to control the signs and symptoms of stuttering.

Methods: Ninety-three patients were recruited in a 12-week single-blind randomized clinical trial, which was held between October 2009 and October 2010. Forty-three patients received olanzapine (5 mg/day) and 50 patients, haloperidol (2.5 mg/day). Before and after the study, they were evaluated by a speech pathologist by Van Riper's questionnaire. The data were analyzed using the SPSS version 16. T-test was used to compare the data between the two groups.

Results: Mean of stuttering score (SD) before treatment was 4.67 (0.81) and 4.40 (1.14) in haloperidol and olanzapine groups, respectively (P > 0.05). After treatment, the mean (SD) score was 2.87 (1.32) and 1.56 (0.71) in haloperidol and olanzapine groups, respectively (P = 0.000).

Conclusions: It seems that olanzapine does have better impact in controlling stuttering, and it may be recommended to prescribe olanzapine for stutters as the first choice to control the stuttering under a careful follow-up.

Citing Articles

A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement Disorders.

Marshall R, Menniti F, Tepper M Cells. 2024; 13(14.

PMID: 39056811 PMC: 11274801. DOI: 10.3390/cells13141230.

Stuttering as a spectrum disorder: A hypothesis.

SheikhBahaei S, Millwater M, Maguire G Curr Res Neurobiol. 2023; 5:100116.

PMID: 38020803 PMC: 10663130. DOI: 10.1016/j.crneur.2023.100116.

Green tea consumption and the management of adrenal stress hormones in adolescents who stutter.

Almudhi A, Gabr S Biomed Rep. 2022; 16(4):32.

PMID: 35251619 PMC: 8889529. DOI: 10.3892/br.2022.1515.

Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering.

Ha C, Maguire G Front Psychiatry. 2021; 12:683368.

PMID: 34759847 PMC: 8574968. DOI: 10.3389/fpsyt.2021.683368.

The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis.

Maguire G, Nguyen D, Simonson K, Kurz T Front Neurosci. 2020; 14:158.

PMID: 32292321 PMC: 7118465. DOI: 10.3389/fnins.2020.00158.

References

Wu J, Huang G, Huang C, Noordhoff M . Nasopharyngoscopic evaluation and cephalometric analysis of velopharynx in normal and cleft palate patients. Ann Plast Surg. 1996; 36(2):117-22; discussion 122-3. DOI: 10.1097/00000637-199602000-00002. View

Maguire G, Riley G, Franklin D, Maguire M, Nguyen C, Brojeni P . Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann Clin Psychiatry. 2004; 16(2):63-7. DOI: 10.1080/10401230490452834. View

Linazasoro G, Van Blercom N . Severe stuttering and motor tics responsive to cocaine. Parkinsonism Relat Disord. 2006; 13(1):57-8. DOI: 10.1016/j.parkreldis.2006.03.007. View

Kumar A, Balan S . Fluoxetine for persistent developmental stuttering. Clin Neuropharmacol. 2007; 30(1):58-9. DOI: 10.1097/01.wnf.0000240950.18821.19. View

Lavid N, Franklin D, Maguire G . Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999; 11(4):233-6. DOI: 10.1023/a:1022365513865. View

Bar K, Hager F, Sauer H . Olanzapine- and clozapine-induced stuttering. A case series. Pharmacopsychiatry. 2004; 37(3):131-4. DOI: 10.1055/s-2004-818992. View

Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X . Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004; 5(3):279-99. DOI: 10.2174/1389450043490514. View

Mathews M, Muzina D . Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med. 2007; 74(8):597-606. DOI: 10.3949/ccjm.74.8.597. View

Chang S, Erickson K, Ambrose N, Hasegawa-Johnson M, Ludlow C . Brain anatomy differences in childhood stuttering. Neuroimage. 2007; 39(3):1333-44. PMC: 2731627. DOI: 10.1016/j.neuroimage.2007.09.067. View

10.

Ingham J, Riley G . Guidelines for documentation of treatment efficacy for young children who stutter. J Speech Lang Hear Res. 1998; 41(4):753-70. DOI: 10.1044/jslhr.4104.753. View

11.

Nurnberg H, Greenwald B . Stuttering: an unusual side effect of phenothiazines. Am J Psychiatry. 1981; 138(3):386-7. DOI: 10.1176/ajp.138.3.386. View

12.

Kumra S, Oberstar J, Sikich L, Findling R, McClellan J, Vinogradov S . Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. 2007; 34(1):60-71. PMC: 2632383. DOI: 10.1093/schbul/sbm109. View

13.

Melkersson K, Gunes A, Dahl M . Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients. Hum Psychopharmacol. 2010; 25(4):347-52. DOI: 10.1002/hup.1114. View

14.

Murray M, Newman R . Paroxetine for treatment of obsessive-compulsive disorder and comorbid stuttering. Am J Psychiatry. 1997; 154(7):1037. DOI: 10.1176/ajp.154.7.1037a. View